Key Takeaways
- Recovery confirmed, guidance intact: Revenue grew 20% in Q2 after a Q1 aberration, and management reiterated 20%+ growth for FY26 with a stronger H2 ahead.
- Backward integration is the margin moat: 79% of revenue is now fully integrated, and the newly operational Module E with larger batch sizes is driving cost efficiencies that support the 33%-35% EBITDA margin guidance.
- The pipeline is broadening beyond APIs: Ambernath finished formulations capitalize in Q3, CDMO contributions start in Q4, and new launches in ADHD, contrast media, and GLP-1 pens are set to diversify revenue streams.
- High-purity anesthetic is a unique, de-risking asset: A 99.97%+ purity API not manufactured in India before, it is an import substitute for China-dependent customers; regulatory filing is imminent but full revenue effect takes two years.
- What to watch next quarter: Ambernath capitalization and revenue guidance, the pace of Whey Protein commercial supply after formulation delays, and any concrete numbers on the GLP-1 finished formulation opportunity.
Revenue Recovery & Growth Drivers
- Q1 was a one-off: The weak Q1 stemmed from a planned de-bottlenecking shutdown essential to get Module E fully operational; Q2's 20% growth confirms the business is back on track, with major recovery still to come in Q3 and Q4.
- Growth composition: Management declined to split the 20% growth into normalization versus structural improvement, arguing the annualized view is the right one; most Q1 spillover orders were executed in Q2, with a residual portion spilling into Q3.
- H2 strength: Higher Q3 growth will be driven mainly by new launches in semi-regulated markets and growth of existing mature products in regulated markets, not just spillover execution.
- Exports dominate: Exports accounted for 81% of Q2 revenue, with Europe and LATAM remaining the largest markets for at least the next two years; North America stays small until USDMF approvals for new launches convert in the next financial year.
- Pricing stability: No negative pricing pressure in regulated markets because products are niche import substitutes from China with limited competition; prices remain stable.
Satish Wagh: "And if we keep on telling everything you are in a country where you are in India, people immediately copy paste. So, nothing will be given as such in detail. That is the worry of the company as far as India is concerned."
Margin Structure & Cost Levers
- EBITDA margin held at 36%: In line with the 33%-35% guidance range, with backward integration and Module E's larger batch sizes as the primary drivers; management reiterated this stabilized margin range for the next couple of years.
- Backward integration depth: 79% of Q2 FY26 revenues are fully integrated, giving the company access to the best cost of material; this is a structural advantage that compounds as volumes scale.
- Module E now fully operational: The new block has much larger reactor capacity and sizes compared to the previous block, directly contributing to cost efficiencies.
- R&D as a margin tool: Continuous lifecycle management at the Lote site focuses on process improvements, eco-friendly replacements of hazardous chemicals, and cost savings, all of which feed back into margins.
- Gross margin opacity: Management maintained its stance of not commenting on gross margins, discussing drivers only at the EBITDA level; an analyst's question on the source of gross margin improvement went unanswered.
- No borrowings: The company has not utilized any borrowings for the last six months, keeping the balance sheet light.
New Product & Facility Pipeline
- Ambernath finished formulation facility: Validation campaigns have started; capitalization expected in Q3, with revenue contribution beginning in Q4; the first phase (liquid anesthetics) already has a good order book and WHO GMP approval, with interest from semi-regulated markets for both tablets and liquid anesthetics.
- Two more launches this fiscal: An ADHD product in Q3 and a contrast media product at the end of Q3 or beginning of Q4; the contrast media R&D is complete and at pilot scale validation.
- Cardiovascular advanced intermediate: Good revenue visibility from Q1 or Q2 of next financial year, with some volume uptake possible in Q4 of this year.
- Large finished formulation partnership: Initial talks are underway; management will comment in the coming few quarters.
- CPHI Frankfurt outcome: Meetings generated firm expectation of good business, exclusively from import substitute products where the company is displacing Chinese suppliers.
High-Purity Anesthetic: A Differentiated Bet
- Unique positioning: This is a 99.97%+ purity API that is bottled directly; no regular version exists, and it has not been manufactured in India before; the product itself has been established globally for 45 years.
- China substitution play: Customers are actively seeking to move away from Chinese non-GMP plants toward a regulated Indian supplier; management stated clients are chasing Supriya for the product, not the reverse.
- Revenue trajectory: Small revenue is already coming from customers taking API for validations and stability studies; USDMF and CEP filing is targeted for end of November; full effect will take two years as the regulatory submission cycle is just starting.
- No price war risk: Because there is no Indian competitor and the alternative is Chinese dependence, management sees no pricing pressure on this product.
Satish Wagh: "Ma'am, you must understand this product, we don't have a competitor in India. We are cracking the China. Business is ample available because people don't want to go with China because they are non-GMP plants. So here we are not chasing for business, but the clients are chasing for their product because they need to change the source and move towards a regulated company like Supriya Lifescience."
CDMO & DSM: The Next Leg
- DSM opportunity commercializing: One CMO/CDMO opportunity has already commercialized; Japanese PMDA approval, CEP, and USDMF approval have been received; food volumes have already started.
- Pharma uptake timeline: Customers have started validation at their site; pharma uptake is expected in another 4 to 5 months.
- DSM full potential: FY27 is when the company expects to reach the INR 60-odd crores of revenue from both pharma and food segments.
- New CDMO projects: 2-3 other projects are in the pipeline on the API advanced intermediate side; management expects to announce two of those in upcoming quarters.
- CDMO commercial contributions: Expected to begin from Q4 of this fiscal year.
Whey Protein & GLP-1: Optionality Bets
- Whey Protein delays: Commercial supply has not yet started because the end customer is still finalizing a novel finished formulation not yet in the Indian market; management expects supply to begin in 1-2 months.
- Volume and revenue trajectory: First-year volumes are expected at about 1,000 tons; the majority of revenue will come in FY27, with full potential expected only in FY28.
- Technology flexibility: The installed technology can handle multiple protein types including milk, pea, and collagen; discussions are ongoing with a Chinese customer for pea protein and in Singapore/Malaysia.
- GLP-1 strategy: The company is targeting finished formulations (injection pens), not API manufacturing in-house; discussions are ongoing with customers in Russia, where the product is not patented; revenue is possible in the next financial year, with business potential guidance expected from Q4 after Ambernath capitalization.
Saloni Wagh: "We are making progress, not as per the expectation. I think by now we should have already started the commercial supply, but we are expecting that to happen very soon. Maybe in about 1 or 2 months' time, it should happen. It is just that they are still deciding on the formulation part with their R&D."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 20%+ for FY26 | FY26 full year |
| EBITDA margin | 33%-35% range | FY26 and next couple of years |
| INR 1,000 crore revenue | On track | By FY27 |
| Product launches | 3-4 this year; ADHD in Q3, contrast media end-Q3/early-Q4 | FY26 |
| Ambernath revenue contribution | Start from Q4 after Q3 capitalization | Q4 FY26 |
| CAPEX | ~INR 80 crores for remaining FY26, primarily maintenance and small projects | FY26 |
| DSM pharma uptake | Customer validation underway | 4-5 months |
| DSM full revenue potential | INR 60-odd crores from pharma and food | FY27 |
| Whey Protein commercial supply | Start in 1-2 months | Near-term |
| Whey Protein full potential | Majority in FY27, full in FY28 | FY28 |
| Anesthetic drug filing | USDMF and CEP filing | End of November |
| New CDMO project announcements | 2 projects to be announced | Upcoming quarters |
| North America revenue increase | Slight increase expected | Next financial year |
| GLP-1 revenue | Possible | Next financial year |
| GLP-1 business potential guidance | From Q4 after Ambernath capitalization | Q4 FY26 |
| Cardiovascular advanced intermediate | Good revenue visibility | Q1/Q2 next financial year |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹200 cr, +20% YoY and +38% QoQ |
| EBITDA | ₹73 cr, +12% YoY and +41% QoQ |
| EBITDA margin | 36%, in line with guidance |
| PAT | ₹50 cr, vs ₹46 cr in Q2 FY25 |
| PAT margin | 25% |
| Exports share | 81% of Q2 FY26 revenues |
| Backward integration | 79% of Q2 FY26 revenues fully integrated |
| H1 FY26 revenue | ₹345 cr, +6% YoY |
| H1 FY26 EBITDA | ₹124 cr, -2.3% YoY |
| H1 FY26 PAT | ₹85 cr, vs ₹91 cr in H1 FY25 |
| CAPEX (Q2 FY26) | ₹28 cr |
| CAPEX (H1 FY26) | ₹42 cr |
| Expected CAPEX for remaining FY26 | ~₹80 cr, primarily maintenance and Ribo Block |
| Full-year CAPEX guidance | ₹80–₹90 cr |
| CWIP | ₹172.5 cr, of which ~₹150–₹155 cr for Ambernath (capitalizing in Q3) |
| Revenue growth guidance (FY26) | ~20% annual growth |
| EBITDA margin guidance | 33%–35% |
| Revenue target | ₹1,000 cr by FY27 |
| New product launches planned (FY26) | 3–4 launches; 2 launched so far, ADHD and contrast media upcoming |
| DSM opportunity peak revenue | ₹60–₹70 cr |
| DSM expected revenue (FY26) | ₹25–₹30 cr |
| Whey Protein capacity | ~3,000 tons per year |
| Whey Protein expected volumes (first year) | ~1,000 tons |
| Cardiovascular advanced intermediate capacity | 1,000 tons; visibility of ~300 tons in advanced discussions |
| Fully backward integrated products | 18 products; 3 more in process, to become 21 |
| Japanese PMDA approval for DSM project | Received |